Edwards Lifesciences (EW) Long-Term Deferred Tax (2009 - 2026)

Edwards Lifesciences' Long-Term Deferred Tax history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 6.84% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 6.84% YoY), while the FY2025 annual figure was $1.1 billion, up 14.72% from the prior year.
• Long-Term Deferred Tax was $1.1 billion for Q1 2026 at Edwards Lifesciences, down from $1.1 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $1.1 billion in Q4 2025 to a low of $294.9 million in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $760.3 million across 5 years, with a median of $776.7 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax surged 98.54% in 2023, then gained 6.84% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $484.0 million in 2022, then jumped by 54.83% to $749.4 million in 2023, then soared by 32.39% to $992.1 million in 2024, then climbed by 14.72% to $1.1 billion in 2025, then decreased by 3.51% to $1.1 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.